TABLE 2.

Identification screening of nucleoside reverse transcriptase inhibitor (NRTI) and non-NRTI DRM

Group and participant ID	Time pointa	Coverage	DRM	Frequency (%)
Maraviroc intensification, MVC+
S2	TP1	8544	K103R	1.10
	TP2	3626	None	None
	TP3	NAb	NA	NA
S3	TP1	6050	E138A	100.00
	TP2	7627	E138A	99.88
	TP3	5117	E138A	99.94
S5	TP1	7615	K103N	100.00
	TP2	2585	K103N	99.96
	TP3	6989	K103N	99.90
S6	TP1	4522	None	None
	TP2	3978	K101E	1.86
	TP3	8258	D67N	2.35
S8	TP1	5661	None	None
	TP2	5598	K65R	17.39
	TP3	7557	None	None
S9	TP1	4564	K65R	2.24
	TP2	6371	None	None
	TP3	7113	None	None
Standard ART regimen
S17	TP1	3895	K103N	94.00
	TP2	4377	K103N	100.00
	TP3	4294	K103N	96.00
S18	TP1	9008	RT103	99.01
	TP2	6662	RT103	100.00
	TP3	NA	NA	NA

^aTP, time point.

^bNA, not available.